Screener
Emergent Biosolutions EBS Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 55.9%+2.4pp | 54.2%+19.0pp | 56.1%+21.4pp | 54.5%+21.0pp | 53.5%+26.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.5×-0.1× | 0.5×-0.1× | 0.5×-0.1× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.4×-0.2× | 4.3×-2.0× | 5×+1.3× | 5.8×+2.9× | 5.7×+4.6× | |
| Leverage | ||||||
| Debt-to-equity | 1.7×+0.5× | 1.1×-0.1× | 1.1×-0.3× | 1.2×-0.2× | 1.3×-1.0× | |
| Per Share | ||||||
| Book value per share | $6.62-33.1% | $9.26-4.0% | $9.22+1.2% | $10.31+12.7% | $9.89+34.7% | |
| Valuation | ||||||
| Market capitalization | $248.16M-43.0% | $428.65M+62.3% | $649.15M+25.3% | $470.56M+6.5% | $367.46M+2.8% | |
| Price / sales | 0.3×-0.2× | 0.6×+0.4× | 0.9×+0.4× | 0.6×+0.2× | 0.4×+0.1× | |
| Price / book | 0.7×-0.1× | 0.8×+0.3× | 1.2×+0.2× | 0.8×-0.1× | 0.7×-0.2× |
FAQ
- What are Emergent Biosolutions's profit margins?
- Emergent Biosolutions (EBS) runs a 55.9% gross margin and a 15.0% operating margin, with a 9.6% net margin.
- Where do Emergent Biosolutions's ratios come from?
- Every ratio is computed from Emergent Biosolutions's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
